[go: up one dir, main page]

DK1996621T3 - Antistoffer mod beta-amyloid-peptid - Google Patents

Antistoffer mod beta-amyloid-peptid

Info

Publication number
DK1996621T3
DK1996621T3 DK07727401.7T DK07727401T DK1996621T3 DK 1996621 T3 DK1996621 T3 DK 1996621T3 DK 07727401 T DK07727401 T DK 07727401T DK 1996621 T3 DK1996621 T3 DK 1996621T3
Authority
DK
Denmark
Prior art keywords
antibodies
beta
amyloid peptide
amyloid
peptide
Prior art date
Application number
DK07727401.7T
Other languages
English (en)
Inventor
Stephen Anthony Burbidge
Jonathan Henry Ellis
Susannah K Ford
Volker Germaschewski
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1996621T3 publication Critical patent/DK1996621T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK07727401.7T 2006-03-30 2007-03-27 Antistoffer mod beta-amyloid-peptid DK1996621T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
PCT/EP2007/052928 WO2007113172A2 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
DK1996621T3 true DK1996621T3 (da) 2010-04-19

Family

ID=38284050

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09178407.4T DK2177536T3 (da) 2006-03-30 2007-03-27 Antistoffer mod amyloid-beta-peptid
DK07727401.7T DK1996621T3 (da) 2006-03-30 2007-03-27 Antistoffer mod beta-amyloid-peptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09178407.4T DK2177536T3 (da) 2006-03-30 2007-03-27 Antistoffer mod amyloid-beta-peptid

Country Status (33)

Country Link
US (3) US8227576B2 (da)
EP (2) EP2177536B1 (da)
JP (1) JP5103466B2 (da)
KR (2) KR20120093400A (da)
CN (2) CN101415729B (da)
AR (1) AR060332A1 (da)
AT (1) ATE451392T1 (da)
AU (1) AU2007233831B2 (da)
BR (1) BRPI0709246A2 (da)
CA (1) CA2647808C (da)
CR (1) CR10347A (da)
CY (1) CY1109877T1 (da)
DE (1) DE602007003703D1 (da)
DK (2) DK2177536T3 (da)
EA (1) EA015654B9 (da)
ES (2) ES2484967T3 (da)
HK (2) HK1138015A1 (da)
HR (2) HRP20100115T1 (da)
IL (1) IL193695A (da)
JO (1) JO2576B1 (da)
MA (1) MA30337B1 (da)
MX (1) MX2008012483A (da)
MY (1) MY149630A (da)
NO (1) NO20083793L (da)
NZ (1) NZ571038A (da)
PE (1) PE20080181A1 (da)
PL (2) PL1996621T3 (da)
PT (2) PT1996621E (da)
SI (2) SI2177536T1 (da)
TW (1) TWI385179B (da)
UA (1) UA94734C2 (da)
WO (1) WO2007113172A2 (da)
ZA (1) ZA200807911B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7892544B2 (en) * 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
MX2010002003A (es) * 2007-08-20 2010-03-10 Glaxo Group Ltd Metodo de produccion.
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JP5642549B2 (ja) 2007-10-12 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 複数の核酸からのタンパク質発現
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
KR101657637B1 (ko) * 2007-12-11 2016-09-19 글락소 그룹 리미티드 항원 결합성 단백질
AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
CL2009001080A1 (es) 2008-05-06 2010-09-24 Glaxo Group Ltd Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2012524030A (ja) 2009-04-20 2012-10-11 アンジオケム インコーポレーテッド Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療
WO2011000095A1 (en) * 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
LT2646470T (lt) 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
MY181743A (en) 2012-05-21 2021-01-06 Genentech Inc Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
WO2014203188A2 (en) 2013-06-19 2014-12-24 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2019006062A1 (en) * 2017-06-29 2019-01-03 The Trustees Of Columbia University In The City Of New York CHIMERIC ANTIBODIES FOR THE TREATMENT OF AMYLOID DETECTION DISEASES
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
WO2020015637A1 (zh) * 2018-07-17 2020-01-23 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
EP3946605A1 (en) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) * 2024-08-19 2024-11-22 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
NZ337765A (en) * 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1133699A1 (en) * 1998-11-25 2001-09-19 Scios Inc. Prevention and treatment of amyloid-associated disorders
SK288711B6 (sk) * 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
CA2426030C (en) * 2000-11-03 2013-12-31 The J. David Gladstone Institutes Methods of treating disorders related to apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof

Also Published As

Publication number Publication date
CY1109877T1 (el) 2014-09-10
PT2177536E (pt) 2014-08-22
PL1996621T3 (pl) 2010-05-31
HK1122311A1 (en) 2009-05-15
IL193695A0 (en) 2011-08-01
JP2009531380A (ja) 2009-09-03
KR20080113273A (ko) 2008-12-29
KR20120093400A (ko) 2012-08-22
PE20080181A1 (es) 2008-03-16
ZA200807911B (en) 2009-11-25
KR101263294B1 (ko) 2013-06-04
AU2007233831A1 (en) 2007-10-11
EP1996621B1 (en) 2009-12-09
MA30337B1 (fr) 2009-04-01
US20160024197A1 (en) 2016-01-28
CR10347A (es) 2008-10-29
CN101415729A (zh) 2009-04-22
US9193784B2 (en) 2015-11-24
ATE451392T1 (de) 2009-12-15
US20110142824A1 (en) 2011-06-16
BRPI0709246A2 (pt) 2011-07-12
NZ571038A (en) 2011-03-31
EA200801842A1 (ru) 2009-02-27
NO20083793L (no) 2008-10-13
ES2338179T3 (es) 2010-05-04
SI2177536T1 (sl) 2014-09-30
PL2177536T3 (pl) 2014-11-28
EP1996621A2 (en) 2008-12-03
MX2008012483A (es) 2008-10-10
SI1996621T1 (sl) 2010-04-30
MY149630A (en) 2013-09-13
EA015654B9 (ru) 2012-01-30
JP5103466B2 (ja) 2012-12-19
UA94734C2 (ru) 2011-06-10
ES2484967T3 (es) 2014-08-12
EP2177536B1 (en) 2014-06-04
PT1996621E (pt) 2010-03-08
CN103539857A (zh) 2014-01-29
IL193695A (en) 2012-05-31
AR060332A1 (es) 2008-06-11
HK1138015A1 (en) 2010-08-13
CA2647808A1 (en) 2007-10-11
WO2007113172A2 (en) 2007-10-11
TW200815466A (en) 2008-04-01
HRP20100115T1 (hr) 2010-04-30
EA015654B1 (ru) 2011-10-31
AU2007233831B2 (en) 2013-02-14
JO2576B1 (en) 2011-02-27
DK2177536T3 (da) 2014-07-14
EP2177536A1 (en) 2010-04-21
US8227576B2 (en) 2012-07-24
CA2647808C (en) 2015-11-17
WO2007113172A3 (en) 2007-11-29
TWI385179B (zh) 2013-02-11
DE602007003703D1 (de) 2010-01-21
HRP20140618T1 (hr) 2014-08-15
CN101415729B (zh) 2013-09-04
US20140050719A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
DK1996621T3 (da) Antistoffer mod beta-amyloid-peptid
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2046826T3 (da) Exendin-fusionsproteiner
DK3118221T3 (da) Proteiner
DK2059533T3 (da) Multispecifikke antistoffer
DK2066695T3 (da) Anti-myostatin-antistoffer
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
EP2211903A4 (en) CLL-1 ANTIBODY
ATE452839T1 (de) Kapsel mit reduziertem nachtropfen
EP2215246A4 (en) PROTEIN SCAFFOLDS
DK2383297T3 (da) Optimerede antistoffer rettet mod CD19
FR2896407B3 (fr) Ambulateur
LU92389I2 (fr) Cystéamine
BRPI0911743A2 (pt) "peptídeo"
BRPI0814971A2 (pt) Proteína
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
DK2035451T3 (da) Insulinoptrop peptidsyntese
FR2909092B1 (fr) Nouveaux anticorps anti-proliferation
EP2212431A4 (en) ANTIBODY AGAINST IREM-1
NO2022038I1 (no) ropeginterferon alfa-2b
DE112007003333A5 (de) Fermenter
DE112008000091A5 (de) Massebondverbindung
DE502007004910D1 (de) Turbolader
AT9745U2 (de) Liegendholzspalter
EP2066601A4 (en) hydrosilylation